{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:18:18Z","timestamp":1788049098534,"version":"build-2784847793"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2025ZNSFSC0694"],"award-info":[{"award-number":["2025ZNSFSC0694"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82574261"],"award-info":[{"award-number":["82574261"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119189","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:02:15Z","timestamp":1785884535000},"page":"119189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Advances in dopamine transporter inhibitors: Design strategies, structural features, and pharmacological insights"],"prefix":"10.1016","volume":"318","author":[{"given":"Hongtao","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruohan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4024-4881","authenticated-orcid":false,"given":"Yiwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejmech.2026.119189_bib1","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3390\/cells10040735","article-title":"Dopamine: the neuromodulator of long-term synaptic plasticity, reward and movement control","volume":"10","author":"Speranza","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2026.119189_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.07.003","article-title":"Dopamine outside the brain: the eye, cardiovascular system and endocrine pancreas","volume":"203","author":"Bucolo","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"8025","key":"10.1016\/j.ejmech.2026.119189_bib3","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41586-024-07739-9","article-title":"Structure of the human dopamine transporter and mechanisms of inhibition","volume":"632","author":"Srivastava","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119189_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00424-013-1410-1","article-title":"The SLC6 transporters: perspectives on structure, functions, regulation, and models for transporter dysfunction","volume":"466","author":"Rudnick","year":"2014","journal-title":"Pfl\u00fcgers Archiv"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119189_bib5","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1038\/s41467-022-30154-5","article-title":"The dopamine transporter antiports potassium to increase the uptake of dopamine","volume":"13","author":"Schmidt","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119189_bib6","series-title":"Parkinson Disease: a Public Health Approach. Technical Brief","year":"2022"},{"issue":"18","key":"10.1016\/j.ejmech.2026.119189_bib7","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3390\/cells13181527","article-title":"Immunotherapy for Parkinson's disease and Alzheimer's Disease: a promising disease-modifying therapy","volume":"13","author":"Mahboob","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2026.119189_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2025.1621887","article-title":"New and emerging pharmacologic treatments for MDD","volume":"16","author":"Uyar","year":"2025","journal-title":"Front. Psychiatr."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119189_bib9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13052-023-01456-1","article-title":"The global prevalence of ADHD in children and adolescents: a systematic review and meta-analysis","volume":"49","author":"Salari","year":"2023","journal-title":"Ital. J. Pediatr."},{"issue":"8025","key":"10.1016\/j.ejmech.2026.119189_bib10","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/s41586-024-07796-0","article-title":"Dopamine reuptake and inhibitory mechanisms in human dopamine transporter","volume":"632","author":"Li","year":"2024","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119189_bib11","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/FPC.0000000000000376","article-title":"PharmGKB summary: methylphenidate pathway, pharmacokinetics\/pharmacodynamics","volume":"29","author":"Stevens","year":"2019","journal-title":"Pharmacogenet. Genom."},{"issue":"45","key":"10.1016\/j.ejmech.2026.119189_bib12","doi-asserted-by":"crossref","first-page":"11122","DOI":"10.1021\/acs.jpclett.1c03133","article-title":"Proteome-Informed machine learning studies of cocaine addiction","volume":"12","author":"Gao","year":"2021","journal-title":"J. Phys. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119189_bib13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/164_2019_251","article-title":"Molecular mechanisms of amphetamines","volume":"258","author":"Reith","year":"2020","journal-title":"Handb. Exp. Pharmacol."},{"issue":"14","key":"10.1016\/j.ejmech.2026.119189_bib14","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1021\/acs.jcim.3c00477","article-title":"Structure-Based discovery of a novel allosteric inhibitor against human dopamine transporter","volume":"63","author":"Deng","year":"2023","journal-title":"J. Chem. Inf. Model."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119189_bib15","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1111\/jnc.16179","article-title":"Cryo-EM structure of the dopamine transporter with a novel atypical non-competitive inhibitor bound to the orthosteric site","volume":"168","author":"Pedersen","year":"2024","journal-title":"J. Neurochem."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119189_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/minf.202400325","article-title":"Machine learning in drug development for neurological diseases: a review of blood brain barrier permeability prediction models","volume":"44","author":"Nabi","year":"2025","journal-title":"Mol. Inf."},{"issue":"8025","key":"10.1016\/j.ejmech.2026.119189_bib17","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41586-024-07804-3","article-title":"Structure of the human dopamine transporter in complex with cocaine","volume":"632","author":"Nielsen","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119189_bib18","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fphar.2015.00235","article-title":"Monoamine transporters: insights from molecular dynamics simulations","volume":"6","author":"Grouleff","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119189_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1150355","article-title":"Overview of the structure and function of the dopamine transporter and its protein interactions","volume":"14","author":"Nepal","year":"2023","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejmech.2026.119189_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126501","article-title":"Advances in metal ion-mediated macromolecular drug delivery","volume":"689","author":"Li","year":"2026","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2026.119189_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2025.113292","article-title":"Preparation of artificial substrate binding sites of nanozyme with \"modular structure\" strategy used for the construction of visual sensing analysis platform for levodopa","volume":"212","author":"Li","year":"2025","journal-title":"Microchem. J."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119189_bib22","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/ddr.21515","article-title":"Structure-activity study of fluorine or chlorine-substituted cinnamic acid derivatives with tertiary amine side chain in acetylcholinesterase and butyrylcholinesterase inhibition","volume":"80","author":"Gao","year":"2019","journal-title":"Drug Dev. Res."},{"issue":"14","key":"10.1016\/j.ejmech.2026.119189_bib23","doi-asserted-by":"crossref","first-page":"7965","DOI":"10.1021\/acs.inorgchem.6c00360","article-title":"Schiff base-wrapped Co, Zn-Based clusters with hierarchical chiral structures for therapeutic application in Parkinson's Disease","volume":"65","author":"Meng","year":"2026","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119189_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.138331","article-title":"Synthesis, bioactivity evaluation and theoretical study of nicotinamide derivatives containing diphenyl ether fragments as potential succinate dehydrogenase inhibitors","volume":"1308","author":"Yan","year":"2024","journal-title":"J. Mol. Struct."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119189_bib25","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.cell.2025.10.034","article-title":"Elucidating pathway-selective biased CCKBR agonism for Alzheimer's disease treatment","volume":"189","author":"Wang","year":"2026","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119189_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13755-025-00370-6","article-title":"CF-DTI: coarse-to-fine feature extraction for enhanced drug-target interaction prediction","volume":"13","author":"Qian","year":"2025","journal-title":"Health Inf. Sci. Syst."},{"issue":"14","key":"10.1016\/j.ejmech.2026.119189_bib27","doi-asserted-by":"crossref","first-page":"6799","DOI":"10.3390\/ijms26146799","article-title":"LSA-DDI: Learning stereochemistry-aware drug interactions via 3D feature fusion and contrastive cross-attention","volume":"26","author":"Wang","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"22","key":"10.1016\/j.ejmech.2026.119189_bib28","doi-asserted-by":"crossref","first-page":"12524","DOI":"10.1021\/acs.jcim.5c02156","article-title":"Cooperative ionic coordination governs dopamine transporter dynamics and substrate translocation: mechanistic insights from molecular simulations","volume":"65","author":"Zhang","year":"2025","journal-title":"J. Chem. Inf. Model."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119189_bib29","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1038\/s41467-025-59511-w","article-title":"Revealing the location and dynamics of a concealed binding site in the dopamine transporter","volume":"16","author":"Zhu","year":"2025","journal-title":"Nat. Commun."},{"issue":"20","key":"10.1016\/j.ejmech.2026.119189_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011234","article-title":"Dopamine transporter imaging, current status of a potential biomarker: a comprehensive review","volume":"22","author":"Palermo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.ejmech.2026.119189_bib31","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1523\/JNEUROSCI.4559-08.2009","article-title":"Physical and functional interaction between the dopamine transporter and the synaptic vesicle protein synaptogyrin-3","volume":"29","author":"Ega\u00f1a","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejmech.2026.119189_bib32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/978-3-031-96364-3_4","article-title":"Regulation of dopamine transporter surface expression","volume":"46","author":"Besada","year":"2025","journal-title":"Adv Neurobiol"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119189_bib33","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/s44321-026-00381-0","article-title":"Alpha-methyl-para-tyrosine and amphetamine ameliorate hyperactivity in a novel mouse model of dopamine transporter deficiency syndrome","volume":"18","author":"Russo","year":"2026","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejmech.2026.119189_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2025.111528","article-title":"Dopamine disruption and autism phenotypes in slc6a3-\/- zebrafish: behavioural and molecular insights","volume":"143","author":"Li","year":"2025","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"25","key":"10.1016\/j.ejmech.2026.119189_bib35","doi-asserted-by":"crossref","first-page":"17691","DOI":"10.1074\/jbc.M800475200","article-title":"An intracellular interaction network regulates conformational transitions in the dopamine transporter","volume":"283","author":"Kniazeff","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119189_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.990405","article-title":"3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: from recreational to novel psychotherapeutic drugs","volume":"13","author":"L\u00f3pez-Arnau","year":"2022","journal-title":"Front. Psychiatr."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119189_bib37","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1124\/pr.108.000869","article-title":"SLC6 neurotransmitter transporters: structure, function, and regulation","volume":"63","author":"Kristensen","year":"2011","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119189_bib38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/(SICI)1096-9861(19990621)409:1<38::AID-CNE4>3.0.CO;2-1","article-title":"Immunocytochemical localization of the dopamine transporter in human brain","volume":"409","author":"Ciliax","year":"1999","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.ejmech.2026.119189_bib39","article-title":"Possible mechanisms underlying the effects of glucagon-like Peptide-1 receptor agonist on cocaine use disorder","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"21","key":"10.1016\/j.ejmech.2026.119189_bib40","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202501472R","article-title":"Transient suppression of dopamine transporter palmitoylation by methamphetamine: implications for transport regulation","volume":"39","author":"Hovde","year":"2025","journal-title":"FASEB J."},{"key":"10.1016\/j.ejmech.2026.119189_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/abp.2025.14488","article-title":"PKC in the perspective of dopamine receptor signaling","volume":"72","author":"Ma","year":"2025","journal-title":"Acta Biochim. Pol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119189_bib42","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.3390\/ijms22063189","article-title":"The role of CaMKII and ERK signaling in addiction","volume":"22","author":"Jia","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119189_bib43","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1096\/fasebj.2022.36.S1.R5533","article-title":"MKP3 overexpression and ERK1\/2 phosphorylation in dopaminergic neurons regulate DAT trafficking and function","volume":"36","author":"Besada","year":"2022","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119189_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00726-021-03104-6","article-title":"Taurine protects dopaminergic neurons in paraquat-induced Parkinson's disease mouse model through PI3K\/Akt signaling pathways","volume":"54","author":"Wang","year":"2022","journal-title":"Amino Acids"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119189_bib45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41531-024-00648-8","article-title":"Silencing Parkinson's risk allele Rit2 sex-specifically compromises motor function and dopamine neuron viability","volume":"10","author":"Kearney","year":"2024","journal-title":"npj Parkinson's Dis."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119189_bib46","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of parkinson disease A review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA, J. Am. Med. Assoc."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119189_bib47","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ana.20089","article-title":"The dopamine transporter: importance in Parkinson's disease","volume":"55","author":"Nutt","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejmech.2026.119189_bib48","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neulet.2013.10.060","article-title":"SLC6A3 is a risk factor for Parkinson's disease: a meta-analysis of sixteen years' studies","volume":"564","author":"Zhai","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejmech.2026.119189_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2026.108294","article-title":"Striatal DAT and disease progression in Parkinson's disease: new evidence from autonomic dysfunction","volume":"146","author":"Zhang","year":"2026","journal-title":"Park. Relat. Disord."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119189_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-20587-5","article-title":"Implication of dopamine transporter and electroencephalography biomarkers in dementia with lewy bodies","volume":"15","author":"Baik","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119189_bib51","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cca.2021.08.009","article-title":"Dopamine in Parkinson's disease","volume":"522","author":"Latif","year":"2021","journal-title":"Clin. Chim. Acta"},{"issue":"37","key":"10.1016\/j.ejmech.2026.119189_bib52","article-title":"Aberrant mitochondrial metabolism in Alzheimer's disease links energy stress with ferroptosis","volume":"12","author":"Alves","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"4","key":"10.1016\/j.ejmech.2026.119189_bib53","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3233\/JAD-161118","article-title":"Therapeutics of neurotransmitters in Alzheimer's disease","volume":"57","author":"Kandimalla","year":"2017","journal-title":"J. Alzheimers Dis."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119189_bib54","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/nn.3843","article-title":"Dopaminergic neurons promote hippocampal reactivation and spatial memory persistence","volume":"17","author":"McNamara","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejmech.2026.119189_bib55","doi-asserted-by":"crossref","DOI":"10.1177\/1759091420925977","article-title":"Early cognitive impairment behind nigrostriatal circuit neurotoxicity: are astrocytes involved?","volume":"12","author":"Herrera","year":"2020","journal-title":"ASN Neuro"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119189_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1523\/ENEURO.0045-21.2021","article-title":"Unique effects of social defeat stress in adolescent male mice on the Netrin-1\/DCC pathway, prefrontal cortex dopamine and cognition (social stress in adolescent vs. adult male mice)","volume":"8","author":"Vassilev","year":"2021","journal-title":"eNeuro"},{"issue":"11","key":"10.1016\/j.ejmech.2026.119189_bib57","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1038\/npp.2014.119","article-title":"Dopaminergic modulation of cortical plasticity in Alzheimer's disease patients","volume":"39","author":"Koch","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119189_bib58","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13195-021-00925-1","article-title":"In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer's disease phases","volume":"13","author":"Sala","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.ejmech.2026.119189_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchemneu.2021.102009","article-title":"Effects of dopamine transporter changes in the ventral tegmental area of the midbrain on cognitive function in aged rats","volume":"117","author":"Xu","year":"2021","journal-title":"J. Chem. Neuroanat."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119189_bib60","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/alz.12776","article-title":"Inhibition of the dopamine transporter promotes lysosome biogenesis and ameliorates Alzheimer's disease-like symptoms in mice","volume":"19","author":"Yin","year":"2023","journal-title":"Alzheimer's Dement."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119189_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/dneu.70023","article-title":"Abnormal behavior of dopamine transporter knockout rats during early ontogeny","volume":"86","author":"Traktirov","year":"2026","journal-title":"Dev. Neurobiol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119189_bib62","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/schbul\/sbr111","article-title":"Striatal presynaptic dopamine in schizophrenia, Part I: meta-analysis of dopamine active transporter (DAT) density","volume":"39","author":"Fusar-Poli","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119189_bib63","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/ijnp\/pyx056","article-title":"Dopamine system dysregulation in major depressive disorders","volume":"20","author":"Belujon","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119189_bib64","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1177\/02698811231200881","article-title":"Dopamine in major depressive disorder: a systematic review and meta-analysis of in vivo imaging studies","volume":"37","author":"Mizuno","year":"2023","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119189_bib65","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bcp.2007.08.007","article-title":"Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction","volume":"75","author":"Rothman","year":"2008","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119189_bib66","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/syn.21538","article-title":"Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder","volume":"66","author":"Bymaster","year":"2012","journal-title":"Synapse"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119189_bib67","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41467-025-66670-3","article-title":"Structural basis for pharmacotherapeutic action of triple reuptake inhibitors","volume":"17","author":"Li","year":"2025","journal-title":"Nat. Commun."},{"issue":"24","key":"10.1016\/j.ejmech.2026.119189_bib68","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1021\/jm990291q","article-title":"Oxygenated analogues of 1-[2-(Diphenylmethoxy)ethyl]- and 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as potential extended-action cocaine-abuse therapeutic agents","volume":"42","author":"Lewis","year":"1999","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119189_bib69","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1208\/aapsj080124","article-title":"Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse","volume":"8","author":"Carroll","year":"2006","journal-title":"AAPS J."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119189_bib70","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1124\/mol.113.088922","article-title":"Binding of mazindol and analogs to the human serotonin and dopamine transporters","volume":"85","author":"Severinsen","year":"2014","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119189_bib71","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00213-024-06723-5","article-title":"Safety and efficacy of dasotraline for patients with attention deficit\/hyperactivity disorder: a systematic review and meta-analysis of 1594 patients including GRADE qualifications","volume":"242","author":"Mansour","year":"2025","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119189_bib72","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.euroneuro.2013.10.007","article-title":"Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET","volume":"24","author":"Appel","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119189_bib73","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.bmc.2010.10.034","article-title":"Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors","volume":"19","author":"Shao","year":"2011","journal-title":"Bioorg. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119189_bib74","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1007\/s00213-013-3391-3","article-title":"Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study","volume":"231","author":"Risinger","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"issue":"15","key":"10.1016\/j.ejmech.2026.119189_bib75","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1111\/bph.16362","article-title":"A novel reuptake inhibitor, IP2015, induces erection by increasing central dopamine and peripheral nitric oxide release","volume":"181","author":"Comerma-Steffensen","year":"2024","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119189_bib76","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/alzrt179","article-title":"The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice","volume":"5","author":"Prior","year":"2013","journal-title":"Alzheimers Res. Ther."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119189_bib77","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1021\/jm040185a","article-title":"Synthesis and monoamine transporter binding properties of 3beta-(3',4'-disubstituted phenyl)tropane-2beta-carboxylic acid methyl esters","volume":"48","author":"Carroll","year":"2005","journal-title":"J. Med. Chem."},{"issue":"28","key":"10.1016\/j.ejmech.2026.119189_bib78","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.2174\/0929867322666150812145631","article-title":"Progress in the search for new dopamine transporter inhibitors","volume":"22","author":"Gryzlo","year":"2015","journal-title":"Curr. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119189_bib79","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/jm050797a","article-title":"1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors","volume":"49","author":"Meltzer","year":"2006","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.ejmech.2026.119189_bib80","doi-asserted-by":"crossref","first-page":"8277","DOI":"10.3390\/ijms22158277","article-title":"The pharmacological profile of second generation pyrovalerone cathinones and related cathinone derivative","volume":"22","author":"Kolaczynska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119189_bib81","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1021\/acsptsci.3c00322","article-title":"Series of (([1,1'-Biphenyl]-2-yl)methyl)sulfinylalkyl alicyclic amines as novel and high affinity atypical dopamine transporter inhibitors with reduced hERG activity","volume":"7","author":"Ku","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119189_bib82","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/biom14060713","article-title":"The structural basis of the activity cliff in modafinil-based dopamine transporter inhibitors","volume":"14","author":"Lee","year":"2024","journal-title":"Biomolecules"},{"issue":"8","key":"10.1016\/j.ejmech.2026.119189_bib83","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s41386-024-01826-1","article-title":"Potential therapeutics for effort-related motivational dysfunction: assessing novel atypical dopamine transport inhibitors","volume":"49","author":"Ecevitoglu","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2026.119189_bib84","doi-asserted-by":"crossref","unstructured":"Xu, Y.; Zeng, H.; Aggarwal, S.; Mortensen, O. V., Novel ways of targeting the dopamine transporter. Adv Neurobiol 46, 271-292.","DOI":"10.1007\/978-3-031-96364-3_11"},{"issue":"8","key":"10.1016\/j.ejmech.2026.119189_bib85","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1523\/JNEUROSCI.4778-04.2005","article-title":"Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine","volume":"25","author":"Desai","year":"2005","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119189_bib86","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1124\/jpet.118.250498","article-title":"Dopamine transporter dynamics of N-Substituted benztropine analogs with atypical behavioral effects","volume":"366","author":"Hong","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2026.119189_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109245","article-title":"Development of benztropine-based DAT blockers for Parkinson's disease interventions: a biologic and synthetic overview","volume":"168","author":"Hern\u00e1ndez-Vel\u00e1zquez","year":"2026","journal-title":"Bioorg. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119189_bib88","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.biopsych.2012.03.022","article-title":"R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse","volume":"72","author":"Loland","year":"2012","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119189_bib89","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3390\/ijms25021041","article-title":"Social interaction in adolescent rats with neonatal ethanol exposure: impact of sex and CE-123, a selective dopamine reuptake inhibitor","volume":"25","author":"Socha","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.ejmech.2026.119189_bib90","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242316956","article-title":"Pharmacokinetics of novel dopamine transporter inhibitor CE-123 and modafinil with a focus on central nervous system distribution","volume":"24","author":"Spreitzer","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119189_bib91","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/s41386-019-0366-z","article-title":"Translating the atypical dopamine uptake inhibitor hypothesis toward therapeutics for treatment of psychostimulant use disorders","volume":"44","author":"Newman","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2026.119189_bib92","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.neuropharm.2017.12.006","article-title":"Atypical dopamine transporter inhibitors attenuate compulsive-like methamphetamine self-administration in rats","volume":"131","author":"Tunstall","year":"2018","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119189_bib93","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.124.002356","article-title":"Contrasting the reinforcing effects of the novel dopamine transport inhibitors JJC8-088 and JJC8-091 in monkeys: potential translation to medication assisted treatment","volume":"392","author":"Allen","year":"2025","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119189_bib94","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41398-025-03391-7","article-title":"RDS-04-010: a novel atypical DAT inhibitor that inhibits cocaine taking and seeking and itself has low abuse potential in experimental animals","volume":"15","author":"Soler-Cedeno","year":"2025","journal-title":"Transl. Psychiatry"},{"issue":"8","key":"10.1016\/j.ejmech.2026.119189_bib95","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1021\/jm0205292","article-title":"Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate","volume":"46","author":"Meltzer","year":"2003","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119189_bib96","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.bjp.0707151","article-title":"Comparisons between bupropion and dexamphetamine in a range of in vivo tests exploring dopaminergic transmission","volume":"150","author":"Bredeloux","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119189_bib97","doi-asserted-by":"crossref","DOI":"10.52965\/001c.81043","article-title":"Bupropion mediated effects on depression, attention deficit hyperactivity disorder, and smoking cessation","volume":"11","author":"Clark","year":"2023","journal-title":"Health Psychol Res"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119189_bib98","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.neuro.2008.06.003","article-title":"Different effects of selective dopamine uptake inhibitors, GBR 12909 and WIN 35428, on HIV-1 Tat toxicity in rat fetal midbrain neurons","volume":"29","author":"Aksenov","year":"2008","journal-title":"Neurotoxicology"},{"issue":"11","key":"10.1016\/j.ejmech.2026.119189_bib99","doi-asserted-by":"crossref","first-page":"8836","DOI":"10.1021\/acs.jmedchem.4c00159","article-title":"Discovery and optimization of tetrahydroisoquinoline derivatives to enhance lysosome biogenesis as preclinical candidates for the treatment of Alzheimer's Disease","volume":"67","author":"Zhou","year":"2024","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119189_bib100","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0028-3908(00)00047-2","article-title":"Alkylation of rat dopamine transporters and blockade of dopamine uptake by EEDQ","volume":"39","author":"Tarazi","year":"2000","journal-title":"Neuropharmacology"},{"issue":"2\u20133","key":"10.1016\/j.ejmech.2026.119189_bib101","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0022-510X(88)90065-2","article-title":"Suppression of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mouse brain by piroheptine and trihexyphenidyl","volume":"83","author":"Saitoh","year":"1988","journal-title":"J. Neurol. Sci."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119189_bib102","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1021\/acschemneuro.4c00589","article-title":"Preclinical profile of CM699 as a medication candidate for stimulant use disorder","volume":"16","author":"Hiranita","year":"2025","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2026.119189_bib103","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuroscience.2011.11.018","article-title":"Lobeline attenuates neonatal ethanol-mediated changes in hyperactivity and dopamine transporter function in the prefrontal cortex in rats","volume":"206","author":"Smith","year":"2012","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.ejmech.2026.119189_bib104","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1210\/en.2009-1184","article-title":"New insights into sexual dimorphism during progression of heart failure and rhythm disorders","volume":"151","author":"Thireau","year":"2010","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119189_bib105","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3390\/ph16030411","article-title":"Efficacy, tolerability, and safety of toludesvenlafaxine for the treatment of major depressive Disorder-A narrative review","volume":"16","author":"Vasiliu","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119189_bib106","doi-asserted-by":"crossref","first-page":"20","DOI":"10.24959\/ophcj.23.268358","article-title":"Biological activities of tetrahydroisoquinolines derivatives","volume":"21","author":"Jordaan","year":"2023","journal-title":"Journal of organic and pharmaceutical chemistry"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119189_bib107","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1527-3458.2006.00123.x","article-title":"Preclinical and clinical pharmacology of DOV 216,303, a \"triple\" reuptake inhibitor","volume":"12","author":"Skolnick","year":"2006","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.ejmech.2026.119189_bib108","doi-asserted-by":"crossref","DOI":"10.1038\/srep34655","article-title":"Antidepressant indatraline induces autophagy and inhibits restenosis via suppression of mTOR\/S6 kinase signaling pathway","volume":"6","author":"Cho","year":"2016","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119189_bib109","doi-asserted-by":"crossref","first-page":"9421","DOI":"10.3390\/molecules16119421","article-title":"Indatraline: synthesis and effect on the motor activity of Wistar rats","volume":"16","author":"Kameyama","year":"2011","journal-title":"Molecules"},{"issue":"1\u20133","key":"10.1016\/j.ejmech.2026.119189_bib110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejphar.2008.04.008","article-title":"In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor","volume":"587","author":"Aluisio","year":"2008","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119189_bib111","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.bcp.2008.01.014","article-title":"Bakuchiol analogs inhibit monoamine transporters and regulate monoaminergic functions","volume":"75","author":"Zhao","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119189_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117538","article-title":"Heterocycle-fused phenylcyclohexylamines as novel multi-target antagonists of N-methyl-D-aspartate (NMDA) receptor and monoamine transporter for treating depression","volume":"291","author":"Zheng","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119189_bib113","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1021\/ml100009p","article-title":"Discovery of WAY-260022, a potent and selective inhibitor of the norepinephrine transporter","volume":"1","author":"Gavrin","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119189_bib114","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1096\/fj.11-195016","article-title":"A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates","volume":"26","author":"Johnston","year":"2012","journal-title":"FASEB J."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119189_bib115","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2174\/0929867330666230120161837","article-title":"NLS-3 (Levophacetoperane or (R,R) phacetoperane): a reverse ester of methylphenidate: a literature review","volume":"31","author":"Konofal","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119189_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118403","article-title":"Discovery of a new allosteric inhibitor for human dopamine transporter by physics-based modeling and experimental validation","volume":"303","author":"Ye","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119189_bib117","series-title":"Characterizing Novel Allosteric Modulators for Human Dopamine Transporter","author":"Yang","year":"2024"},{"key":"10.1016\/j.ejmech.2026.119189_bib118","series-title":"Functional Studies of a Dopamine Transporter Allosteric Modulator and Its Effect on cocaine-induced Behavior","author":"Xu","year":"2020"},{"key":"10.1016\/j.ejmech.2026.119189_bib119","series-title":"Behavioral and Biochemical Studies of Novel Allosteric Modulators of the Dopamine Transporter with Therapeutic Potential","author":"Rice","year":"2019"},{"issue":"10","key":"10.1016\/j.ejmech.2026.119189_bib120","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.neuron.2023.02.017","article-title":"Propofol exerts anti-anhedonia effects via inhibiting the dopamine transporter","volume":"111","author":"Zhu","year":"2023","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.ejmech.2026.119189_bib121","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1021\/acs.jctc.2c00002","article-title":"Machine learning analysis of cocaine addiction informed by DAT, SERT, and NET-Based interactome networks","volume":"18","author":"Feng","year":"2022","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2026.119189_bib122","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/bs.pbr.2018.08.005","article-title":"Ibogaine as a treatment for substance misuse: potential benefits and practical dangers","volume":"242","author":"Corkery","year":"2018","journal-title":"Prog. Brain Res."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119189_bib123","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1124\/jpet.108.149088","article-title":"Studies of the biogenic amine transporters. 13. Identification of \"agonist\" and \"antagonist\" allosteric modulators of amphetamine-induced dopamine release","volume":"329","author":"Rothman","year":"2009","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119189_bib124","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1124\/jpet.118.250902","article-title":"Interactions between cocaine and the putative allosteric dopamine transporter ligand SRI-31142","volume":"367","author":"Moerke","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119189_bib125","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1124\/jpet.114.222299","article-title":"Studies of the biogenic amine transporters 15. Identification of novel allosteric dopamine transporter ligands with nanomolar potency","volume":"353","author":"Rothman","year":"2015","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119189_bib126","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.tips.2020.04.006","article-title":"Allosteric modulation of neurotransmitter transporters as a therapeutic strategy","volume":"41","author":"Niello","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119189_bib127","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.124.002138","article-title":"Identification of pyrimidine structure-based compounds as allosteric ligands of the dopamine transporter as therapeutic agents for NeuroHIV","volume":"392","author":"Jimenez-Torres","year":"2025","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"14","key":"10.1016\/j.ejmech.2026.119189_bib128","doi-asserted-by":"crossref","first-page":"7881","DOI":"10.3390\/ijms25147881","article-title":"Effects of SRI-32743, a novel quinazoline structure-based compound, on HIV-1 tat and cocaine interaction with norepinephrine transporter","volume":"25","author":"Jim\u00e9nez-Torres","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119189_bib129","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.tips.2025.10.002","article-title":"Discovering next-generation dopamine transporter drugs with lower abuse potential","volume":"46","author":"Luo","year":"2025","journal-title":"Trends Pharmacol. Sci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:14:08Z","timestamp":1788048848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426006343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":129,"alternative-id":["S0223523426006343"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119189","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in dopamine transporter inhibitors: Design strategies, structural features, and pharmacological insights","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119189","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119189"}}